Pharmacokinetics of 23-Epi-26-deoxyactein in women after oral administration of a standardized extract of black cohosh

R. B. Van Breemen, W. Liang, S. Banuvar, L. P. Shulman, Y. Pang, Y. Tao, D. Nikolic, K. M. Krock, D. S. Fabricant, S. N. Chen, S. Hedayat, J. L. Bolton, G. F. Pauli, C. E. Piersen, E. C. Krause, S. E. Geller, N. R. Farnsworth

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Abstract

Dietary supplements containing black cohosh are alternatives to conventional hormone replacement therapy in menopause. This study investigates the maximum tolerated dose of a 75% ethanol extract of black cohosh and determines the pharmacokinetics of one of its most abundant triterpene glycosides, 23-epi-26-deoxyactein. Single doses of black cohosh extract containing 1.4, 2.8, or 5.6mg of 23-epi-26-deoxyactein were administered to 15 healthy, menopausal women. Serial blood samples and 24-h urine samples were obtained; blood chemistry, hormonal levels, and 23-epi-26-deoxyactein levels were determined. No acute toxicity or estrogenic hormone effects were observed. Pharmacokinetic analyses of 23-epi-26-deoxyactein in sera indicated that the maximum concentration and area under the curve increased proportionately with dosage, and that the half-life was ∼2h for all dosages. Less than 0.01% of the 23-epi-26-deoxyactein was recovered in urine 24h after administration. No phase I or phase II metabolites were observed either in clinical specimens or in vitro.

Original languageEnglish (US)
Pages (from-to)219-225
Number of pages7
JournalClinical pharmacology and therapeutics
Volume87
Issue number2
DOIs
StatePublished - Feb 2010

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Pharmacokinetics of 23-Epi-26-deoxyactein in women after oral administration of a standardized extract of black cohosh'. Together they form a unique fingerprint.

Cite this